Flyrcado is a diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Join cardiovascular experts across the U.S. preparing to expand access to cardiac PET. Flyrcado Forward, GE HealthCare’s program of peer-to-peer education and training for cardiac PET imaging centers, is here to help.

Gain greater diagnostic certainty in CAD

Flyrcado delivers precision in imaging¹ and superior diagnostic accuracy over SPECT—even for challenging-to-image patients.^2,3

With on-demand unit doses delivered up to 5 days a week and a 109-minute half-life,^1,2,4,5 Flyrcado enables operational flexibility for exercise stress testing and re-imaging due to technical difficulties, when needed, without re-dosing.^2,4

Flyrcado brings cardiac PET to imaging centers in a broader range of sizes and locations^4,5,7

Be Flyrcado Forward

Join your peers in the effort to expand access to cardiac PET imaging with the support of Flyrcado Forward. Sign up today for education and training opportunities with leading investigators and clinicians as you prepare to bring Flyrcado to your site of care. 

References

1. Maddahi J, Packard RRS. Cardiac PET perfusion tracers: current status and future directions. Semin Nucl Med. 2014;44(5):333-343.
2. Flyrcado (flurpiridaz F 18 injection) . Full Prescribing Information. Marlborough, MA: GE HealthCare.
3. Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET Myocardial perfusion imaging in patients with suspected coronary artery disease. J Am Coll Cardiol. 2023;82(16):1598-1610.
4. Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. Curr Cardiol Rep. 2022;24(8):987-994.
5. Driessen RS, Raijmakers PG, Stuijfzand WJ, Knaapen P. Myocardial perfusion imaging with PET. Int J Cardiovasc Imaging. 2017;33(7):1021-1031.
6. Iskandrian AE, Dilsizian V, Garcia EV, et al. Myocardial perfusion imaging: lessons learned and work to be done update. J Nucl Cardiol. 2018;25(1):39-52.
7. Bourque JM. Cardiac PET perfusion imaging: AURORA lights the way to a new era. J Am Coll Cardiol. 2023;82(16):1611-1613.

Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Contraindications

None

Warnings and Precautions

• Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information. 
• Radiation risks: FLYRCADO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.

Adverse Reactions

• Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch

Please see the full Prescribing Information for additional important safety information.